Hybio Pharmaceutical Co., Ltd. (SHE:300199)
23.75
-0.17 (-0.71%)
Oct 8, 2026, 3:04 PM CST
Hybio Pharmaceutical Revenue
Hybio Pharmaceutical had revenue of 389.14M CNY in the quarter ending June 30, 2026, with 62.50% growth. This brings the company's revenue in the last twelve months to 1.11B, up 25.03% year-over-year. In the year 2025, Hybio Pharmaceutical had annual revenue of 966.35M with 63.73% growth. That makes Hybio Pharmaceutical the 18,876th largest company in the world by revenue and 3,439th in China.
Revenue (ttm)
1.11B
Revenue Growth
+25.03%
P/S Ratio
18.98
Revenue / Employee
901.47K
Employees
1,226
Market Cap
20.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 966.35M | 376.15M | 63.73% |
| Dec 31, 2024 | 590.20M | 158.81M | 36.82% |
| Dec 31, 2023 | 431.38M | -272.94M | -38.75% |
| Jan 1, 2023 | 704.32M | -31.65M | -4.30% |
| Jan 1, 2022 | 735.97M | 14.25M | 1.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsHybio Pharmaceutical News
- 3 months ago - US Food and Drug Administration to review Hybio's generic GLP-1s - Reuters